Targeting of Inhaled Therapeutics to the Small Airways: Nanoleucine Carrier Formulations
Current dry powder formulations for inhalation deposit a large fraction of their emitted dose in the upper respiratory tract where they contribute to off-target adverse effects and variability in lung delivery. The purpose of the current study is to design a new formulation concept that more effecti...
Saved in:
Main Authors: | Danforth P. Miller (Author), Thomas E. Tarara (Author), Jeffry G. Weers (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2021-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Optimizing Spray-Dried Porous Particles for High Dose Delivery with a Portable Dry Powder Inhaler
by: Yoen-Ju Son, et al.
Published: (2021) -
Suboptimal Inspiratory Flow Rates With Passive Dry Powder Inhalers: Big Issue or Overstated Problem?
by: Jeffry Weers
Published: (2022) -
Future of Carrier-Free Dry Powder Inhaler Formulations
by: Ali Nokhodchi, et al.
Published: (2024) -
Inhaled RNA Therapeutics for Obstructive Airway Diseases: Recent Advances and Future Prospects
by: You Xu, et al.
Published: (2021) -
Inhaled Medicines for Targeting Non-Small Cell Lung Cancer
by: Arwa Omar Al Khatib, et al.
Published: (2023)